NewsRoom Articles - Page 557 of 1255

TuesdayOct 29, 2019 2:25 pm

Athersys Inc. (NASDAQ: ATHX) Starts Presentation at Dawson James Small Cap Growth Conference

Athersys (NASDAQ: ATHX) is working to change the future of medicine. A clinical-stage biotechnology company, Athersys is developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. With a focus on developing therapies in regenerative medicine, Athersys is developing therapeutic products the company believes have best-in-class potential. The company's lead platform product, MultiStem cell therapy, has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas. Its most advanced program focused on the treatment of ischemic stroke is in a phase 3 clinical trial. Athersys' wide ranging clinical development…

TuesdayOct 29, 2019 2:25 pm

Celsion Corp. (NASDAQ: CLSN) Starts Presentation at Dawson James Small Cap Growth Conference

Celsion (NASDAQ: CLSN) is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Celsion's mission is to transform the landscape of cancer treatment with novel targeting technologies. The company's lead product candidate is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase 3 trial combined with RFA for the treatment of hepatocellular carcinoma. Second in Celsion's pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian cancer. Celsion has 3 platform technologies providing the basis for the development of a range…

TuesdayOct 29, 2019 2:00 pm

Mesoblast Ltd. (NASDAQ: MESO) Starts Presentation at Dawson James Small Cap Growth Conference

A global leader in cellular medicines for inflammatory diseases, Mesoblast (NASDAQ: MESO) is developing allogeneic (off-the-shelf) cellular medicines. Mesoblast leverages its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor without the…

TuesdayOct 29, 2019 2:00 pm

AzurRx BioPharma Inc. (NASDAQ: AZRX) Starts Presentation at Dawson James Small Cap Growth Conference

AzurRx BioPharma (NASDAQ: AZRX) is a business-led, science-driven, and clinically advanced development-stage biopharmaceutical company. AzurRx BioPharma is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's lead development program, MS1819, is a recombinant lipase for the treatment of exocrine pancreatic insufficiency indicated for cystic fibrosis and chronic pancreatitis patients. AZX1103 is a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. AzurRx BioPharma's core technologies of next-generation enzymes are novel, advanced therapeutic and represent the next forward in the fight to treat diseases that impact daily life and the ability…

TuesdayOct 29, 2019 1:54 pm

ORHub Inc. (ORHB) – Surgical Spotlight® for Health Care Providers

ORHub Inc. is a health care intelligence company which develops data analytics software solutions to bring lean process improvement to the business of surgery ORHub developed Surgical Spotlight®, a program that is used to gather the real-time data from the operating room to provide comprehensive and intuitive dashboards used by physicians and administrators to help reduce costs and improve efficiency An interview done recently with Dr. Kevin Kaplan recaps the benefits of ORHub’s Surgical Spotlight®, and how he successfully applied the tool to his practice ORHub Inc. (OTC: ORHB) is a health care intelligence company that is involved in the…

TuesdayOct 29, 2019 1:35 pm

Hoth Therapeutics Inc. (NASDAQ: HOTH) Starts Presentation at Dawson James Small Cap Growth Conference

Hoth Therapeutics (NASDAQ: HOTH) is focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent…

TuesdayOct 29, 2019 1:35 pm

Sophiris Bio Inc. (NASDAQ: SPHS) Starts Presentation at Dawson James Small Cap Growth Conference

A late-stage, clinical biopharmaceutical company, Sophiris Bio (NASDAQ: SPHS) is developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin, a first-in-class, pore-forming protein, is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations around prostate tumor cells and in the transition zone of the prostate. Topsalysin has completed two phase 2 clinical trials for the focal treatment of localized prostate cancer as well as one Phase 3 clinical trial for the treatment of the lower urinary tract symptoms of benign…

TuesdayOct 29, 2019 1:20 pm

CloudCommerce Inc. (CLWD) Brings Micro-Targeting to Brand Distributers, Marketers

CloudCommerce’s business intelligence solution, SWARM, incorporates micro-targeting tools The exclusive solution is backed by CloudCommerce subsidiaries’ expertise and technologies The business intelligence market is forecast to reach $34.3 billion by 2022 Micro-targeting is now available to brand distributers and other marketers, thanks to organizations such as CloudCommerce Inc. (OTCQB: CLWD). The company, a provider of audience-driven business-intelligence and marketing solutions, has developed a menu of tools that utilizes consumer data and demographics to create audience subsets or segments. This information allows businesses to deliver fine-tuned marketing communications that are not only more effective because they are free of irrelevant messaging,…

TuesdayOct 29, 2019 1:10 pm

CollPlant (NASDAQ: CLGN) Starts Presentation at Dawson James Small Cap Growth Conference

CollPlant (NASDAQ: CLGN) is focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics and advanced wound care markets. The company's products are based on its rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology. CollPlant's products address indications for the diverse fields of organ and tissue repair. The company's flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. Last year, CollPlant entered into a licensing agreement with United Therapeutics, and United Therapeutics is now using BioInks in the manufacture of…

TuesdayOct 29, 2019 1:10 pm

AIM ImmunoTech Inc. (NYSE: AIM) Starts Presentation at Dawson James Small Cap Growth Conference

AIM ImmunoTech Inc. (NYSE: AIM) is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. The company's flagship products include the Argentina-approved drug rintatolimod (Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. Rintatolimod is a double-stranded…

Financial news and publishing for public and private companies

Contact us: 212.418.1217